Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TEA001
- Development stage
- Preclinical
- Lead developer
- Apteeus
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
TEA001 is an inhaled anti-infectious drug candidate being developed by Apteeus through its subsidiary APTEEA Therapeutics. It is a reformulation of an existing, approved active pharmaceutical ingredient with antimicrobial properties, specifically designed for delivery via a latest-generation inhalation device. The development program targets common pulmonary pathologies and respiratory infections with significant unmet medical needs, particularly in elderly patients or those with respiratory insufficiency. Currently in preclinical development, TEA001 aims to provide a more effective and targeted treatment for lung infections by delivering the drug directly to the site of infection.
Beyond the preview
Go deeper on TEA001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TEA001.